Monday, September 27, 2021
5:30 pm – 8:30 pm
at La Jolla Playhouse
David F. Hale
Chairman & CEO, Hale BioPharma Ventures, LLC
David F. Hale is Chairman and CEO of Hale BioPharma Ventures, LLC a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. Mr. Hale is a serial entrepreneur who has been involved in the formation and development of a number of successful biomedical companies. He served as Chairman of Santarus, Inc., prior to its sale to Salix Pharmaceuticals, Inc. in 2014, SkinMedica, Inc., prior to its sale to Allergan in 2012, Micromet, Inc., prior to its sale to Amgen Inc. in 2012, Somaxon Pharmaceuticals, prior to its sale to Pernix in 2013, Crisi Medical Systems, prior to its sale to Becton-Dickinson in 2015, and Agility Clinical, prior to its sale to Precision Medicine in 2017. In 1982, after joining Hybritech, Inc., the first biotechnology company in San Diego, he served as COO, President and then CEO, when Hybritech was acquired by Eli Lilly and Co. in 1986. From 1987 to 1997, he was Chairman, President and CEO of Gensia, Inc., which merged with SICOR to become Gensia Sicor, Inc., which was acquired by Teva Pharmaceuticals. He was a co-founder and Chairman of Viagene, Inc. from 1987 to 1995, when Viagene was acquired by Chiron, Inc. In 1997, he was a co-founder and served as Chairman of LMA North America until its merger with LMA International in 2004. He joined CancerVax in October 2000, where he served as President and CEO from 2000 until its merger with Micromet, Inc, in 2006, when he became Chairman. He currently serves on the board of two public companies, Oncternal Therapeutics, Inc., as Chairman, and BIOCEPT, Inc. He also serves on the Board of Directors of private companies Zerigo Health, Inc., Recros Medica, Inc., and Adigica Health, Inc. He is a co-founder and Chairman of Neurana Pharmaceuticals, Inc., a co-founder and Director of Neurelis, Inc., a co-founder and Managing Member of Dermata Therapeutics, Inc., and a co-founder of Cadence, Evoke, Elevation and Zogenix. Prior to joining Hybritech, Hale was Vice President and General Manager of BBL Microbiology Systems, a division of Becton, Dickinson & Co. and from 1971 to 1980, held various marketing and sales management positions with Ortho Pharmaceutical Corporation, a division of Johnson & Johnson, Inc. Mr. Hale is a co-founder and serves on the Board of Directors of BIOCOM and CONNECT and is a former member of the Board of the Biotechnology Industry Organization (BIO), and the Biotechnology Institute. He has served on the Board of Rady Children’s Hospital since 1986, including Chairman of the Board from 2011 to 2015, and is founder and Chairman of the Rady Children’s Institute of Genomic Medicine. He serves on the University of San Diego Board of Trustees, is a member of the UCSD Rady School of Management Dean’s Advisory Council, and a Director of the San Diego Economic Development Corporation.
Special performances by String Theory throughout the evening.
String Theory is a hybrid performance ensemble combining signature architectural harp installations, original music, dance and projections. L.A.’s genre-bending group continues to transfix audiences in the U.S. and abroad with their long-string harp installations, where architecture is transformed into giant musical instruments, spaces become resonators, and audiences are enveloped in an expansive site-specific canopy of golden musical brass wire and sound. Rock, classical and cutting-edge digital styles converge in a lush and compelling soundtrack supporting kinetic contemporary movement, with stunning costumes and projections, creating an immersive, multi-sensory environment.
COVID-19 Safety: This is an outdoor, open-air event. All attendees must show proof of vaccination or provide a negative PCR COVID-19 test taken within 48 hours of the event. Click button below to learn more.
Gallery Hosts: Biocept, DTx Pharma, Hale BioPharma, Illumina, IQHQ, Luna DNA, Marsh & McLennan, Neurelis, Oncternal Therapuetics, Qualcomm, Rady Children’s Hospital Foundation, SDSU Research and Innovation, Stockdale Capital Partners LLC, TEGA Therapeutics, UC San Diego
If you are unable to attend, please consider supporting innovation at the Playhouse by clicking here: INNOVATE.givesmart.com
To purchase tickets, please email Sam Watkins, Corporate Relations Manager, at [email protected] or India Benedetto, Institutional Giving Coordinator, at [email protected].
Tickets are available NOW for $250.
Amazing sponsorship opportunities start at just $7,500! For more information, please contact Samantha Watkins, Corporate Relations Manager,
at [email protected] or (858) 228-3078.
Thank you to our generous sponsors who have committed to support La Jolla Playhouse:
Chair: Tim Scott, CEO, TEGA Therapeutics
Gordon Alton, CEO and President, Agragene Inc.
Denise Bevers, COO, DTx Pharma
Charles Black, Managing Director, J.P. Morgan Private Bank
Jim Breitmeyer, M.D., Ph.D., President and CEO, Oncternal Therapeutics Inc.
Carin Canale-Theakston, Chief Executive Officer, CanaleComm
Jennifer Cayer, Chief Business Officer, Pulmocide Limited
Anna E. Diaz, Principal, Lead Advisor, Dowling & Yahnke Wealth Advisors
Leo Divinsky, Managing Director of Asset Management, Stockdale Capital Partners, LLC
Brian Dovey, Partner, Domain Associates
Susan Dube, Founder and CFO of Sorriso Pharmaceuticals, Inc.
John Dunn, General Counsel and Corporate Secretary, Vital Therapies Inc.
Stephen C. Ferruolo, Partner, Perkins Coie LLP
Patrick Frias, M.D., President & Chief Executive Officer Rady Children’s Hospital and Health Center-San Diego
Jeff Friedman, Managing Partner, Friedman Bioventure
Wendy Gillespie, CEO, Starhawk Productions
Gerardo Godinez, Partner in Charge, Moss Adams
Clark Guy, Managing Director, Market Executive, Bank of America Private Bank
Susie Harborth, EVP Business Operations Breakthrough Properties, Mission BioCapital
Greg Horowitt, Co-Founder & Managing Director, T2 Venture Capital
Vyomesh Joshi, CEO & President, 3D Systems
Bob Kain, Co-Founder and Chairman, Luna DNA
Bryan Knox, General Manager, Catalent
Mike Krenn, CEO, Connect
James MacKay, CEO, Aristea Therapeutics
Stanley Maloy, Associate Vice President for Research & Innovation, San Diego State University
Magda Marquet, Founder and Co-Chair, Althea
Chris Montgomery, SVP, Business Development, Cooley
Julie Stone Moran, San Diego Office Marketplace Leader, Deloitte
Tom Murphy, Senior Vice President, Bench International
Mike Nall, President and CEO, Biocept
Joe Panetta, CEO & President, Biocom
Bernard Parker, Managing Director, Caligen Bio
Richard W. Pascoe, President and CEO, Histogen, Inc
Robert Price, Managing Director, TI Management
Christopher A. and Sharon Lee Rhodes, Baywind Bioventures
Don Rosenberg, Executive Vice President, General Counsel and Corporate Strategy, Qualcomm
Ivor Royston, President and CEO, Viracta
Drew Senyei, Managing Director, Enterprise Partners Venture Capital
Natalie Sherod, Risk Advisor, Cavignac
Larry Stambaugh, Principal, Apercu Partners
Juli Stone Moran, San Diego Office Marketplace Leader, Deloitte
Kelly Thomson, Regional Managing Director, Ascent Private Capital Management of U.S. Bank
Mary Walshok, Associate Vice Chancellor for Public Programs, UC San Diego
David Webb, Adjunct Professor/CEO, Scripps Research Institute/Synbal Inc.
Lorelei Westin, Member, Wilson Sonsini Goodrich & Rosati
Sign up to our email list and be the first to know about show announcements, ticket on-sales and special events.
By providing your cell, you agree to automated text messages for show reminders and occasional announcements. Rates may apply.